Provides air transportation of human organs for transplant. Offers ground transportation of human organs for transplant. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
Average growth of 41% a year over the last 4 years. Red columns mark years that ended in a loss.
If every debt were paid off today, $57.9M would still be left in the vault — a solid cushion for hard times.
The market pays 10.9× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
Against companies in its own sector, it looks cheaper than 72% of them.
Analysts' average target sits 40% above today's price.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
The stock trades 53% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 21% — still a thick cushion, though costs have been eating into it lately.
Over the last 4 years, sales grew about 41% a year on average.
There is $61.2M in the vault; even if every debt were paid off, $57.9M would remain.
This stock swings about 2.3 times as much as the market average. Big rallies — and big drops — can both happen fast.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 35/100.
Since the drop from its peak, buyer appetite hasn’t come back.
On our five-subject report card, SRTA sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: SRTA is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.